{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:44:32Z","timestamp":1789789472796,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Xi'an Science and technology plan project","award":["23YXYJ0065"],"award-info":[{"award-number":["23YXYJ0065"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-025-04014-z","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T10:16:49Z","timestamp":1763461009000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Construction and clinical application of an innovative pharmacist-led service model for therapeutic drug monitoring in tuberculosis treatment: a pragmatic randomized controlled trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Qian","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyun","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guolian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaogang","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxia","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"4014_CR1","unstructured":"World health organization. Global tuberculosis report. 2024. Geneva: World Health Organization; 2024."},{"issue":"6","key":"4014_CR2","doi-asserted-by":"publisher","first-page":"e570","DOI":"10.1016\/S2666-5247(24)00022-3","volume":"5","author":"S Stanley","year":"2024","unstructured":"Stanley S, Spaulding CN, Liu Q, et al. Identification of bacterial determinants of tuberculosis infection and treatment outcomes: a phenogenomic analysis of clinical strains. Lancet Microbe. 2024;5(6):e570\u201380. https:\/\/doi.org\/10.1016\/S2666-5247(24)00022-3.","journal-title":"Lancet Microbe"},{"key":"4014_CR3","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.ijid.2020.01.041","volume":"92S","author":"JC Alffenaar","year":"2020","unstructured":"Alffenaar JC, Akkerman OW, Kim HY, et al. Precision and personalized medicine and anti-TB treatment: is TDM feasible for programmatic use? Int J Infect Dis. 2020;92S:S5\u20139. https:\/\/doi.org\/10.1016\/j.ijid.2020.01.041.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"4014_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/17425255.2021.1836158","volume":"17","author":"A Martson","year":"2021","unstructured":"Martson A, Burch G, Ghimire S, et al. Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems. Expert Opin Drug Metab Toxicol. 2021;17(1):23\u201339. https:\/\/doi.org\/10.1080\/17425255.2021.1836158.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"4014_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106297","volume":"57","author":"A Trentalange","year":"2021","unstructured":"Trentalange A, Borgogno E, Motta I. Rifampicin and isoniazid maximal concentrations are below efficacy-associated thresholds in the majority of patients: time to increase the doses? Int J Antimicrob Agents. 2021;57(3):106297. https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106297.","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"4014_CR6","doi-asserted-by":"publisher","first-page":"e3520","DOI":"10.1093\/cid\/ciaa1569","volume":"73","author":"X Zheng","year":"2021","unstructured":"Zheng X, Bao Z, Forsman LD, et al. Drug exposure and minimum inhibitory concentration predict pulmonary tuberculosis treatment response. Clin Infect Dis. 2021;73(9):e3520\u20138. https:\/\/doi.org\/10.1093\/cid\/ciaa1569.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"4014_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.5428\/pcar20200212","volume":"20","author":"\u0f39 Zhao","year":"2020","unstructured":"Zhao \u0f39, \u0f37ang \u0f28, Zhou \u0f2a, et al. Application of quality control circle in reducing the rate of abnormal low values of Isoniazid in blood concentration monitoring. Pharm Care Res. 2020;20(2):132\u20136. https:\/\/doi.org\/10.5428\/pcar20200212.","journal-title":"Pharm Care Res"},{"issue":"41","key":"4014_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017523","volume":"98","author":"Q Lei","year":"2019","unstructured":"Lei Q, Wang H, Zhao Y, et al. Determinants of serum concentration of first-line anti-tuberculosis drugs from China. Medicine. 2019;98(41):e17523. https:\/\/doi.org\/10.1097\/MD.0000000000017523.","journal-title":"Medicine"},{"issue":"1","key":"4014_CR9","first-page":"59","volume":"3","author":"The national health and family planning commission of the people\u2019","year":"2018","unstructured":"The national health and family planning commission of the people\u2019. S Republic of China diagnostic criteria for pulmonary tuberculosiS (WS 288\u20132017). Electron J Emerg Infect Dis. 2018;3(1):59\u201361.","journal-title":"Electron J Emerg Infect Dis"},{"issue":"8","key":"4014_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.8667","volume":"34","author":"Q Lei","year":"2020","unstructured":"Lei Q, Zhao Y, Wang H, et al. Simple and sensitive method for the analysis of 14 antituberculosis drugs using liquid chromatography\/tandem mass spectrometry in human plasma. Rapid Commun Mass Spectrom. 2020;34(8):e8667. https:\/\/doi.org\/10.1002\/rcm.8667.","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"8","key":"4014_CR11","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","volume":"74","author":"A Alsultan","year":"2014","unstructured":"Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74(8):839. https:\/\/doi.org\/10.1007\/s40265-014-0222-8.","journal-title":"Drugs"},{"key":"4014_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2025.107880","volume":"155","author":"T Alonzi","year":"2025","unstructured":"Alonzi T, Petruccioli E, Aiello A, et al. Diagnostic tests for tuberculosis infection and predictive indicators of disease progression: utilizing host and pathogen biomarkers to enhance the tuberculosis elimination strategies. Int J Infect Dis. 2025;155:107880. https:\/\/doi.org\/10.1016\/j.ijid.2025.107880.","journal-title":"Int J Infect Dis"},{"key":"4014_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ijid.2014.12.007","volume":"32","author":"E Skoura","year":"2015","unstructured":"Skoura E, Zumla A, Bomanji J. Imaging in tuberculosis. Int J Infect Dis. 2015;32:87\u201393. https:\/\/doi.org\/10.1016\/j.ijid.2014.12.007.","journal-title":"Int J Infect Dis"},{"issue":"11","key":"4014_CR14","first-page":"1069","volume":"47","author":"Chinese medical association tuberculosis branch","year":"2024","unstructured":"Chinese medical association tuberculosis branch. Guidelines for diagnosis and management of drug-induced liver injury caused by anti-tuberculosis drugs (2024 version). Chin J Tubere Respir Dis. 2024;47(11):1069\u201390.","journal-title":"Chin J Tubere Respir Dis"},{"key":"4014_CR15","unstructured":"National cancer institute. Common terminology criteria for adverse events (CTCAE) version 5.0. Bethesda, MD: National Cancer Institute. 2017. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed 15 Mar 2025."},{"issue":"7","key":"4014_CR16","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1093\/cid\/ciw376","volume":"63","author":"P Nahid","year":"2016","unstructured":"Nahid P, Dorman SE, Alipanah N, et al. Official American thoracic society\/centers for disease control and prevention\/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147\u201395. https:\/\/doi.org\/10.1093\/cid\/ciw376.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"4014_CR17","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","volume":"200","author":"P Nahid","year":"2019","unstructured":"Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis. An official ATS\/CDC\/ERS\/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019;200(10):e93\u2013142. https:\/\/doi.org\/10.1164\/rccm.201909-1874ST.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"4014_CR18","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/cid\/ciy179","volume":"67","author":"C Sekaggya-Wiltshire","year":"2018","unstructured":"Sekaggya-Wiltshire C, von Braun A, Lamorde M, et al. Delayed sputum culture conversion in tuberculosis-human immunodeficiency virus-coinfected patients with low isoniazid and rifampicin concentrations. Clin Infect Dis. 2018;67(5):708\u201316. https:\/\/doi.org\/10.1093\/cid\/ciy179.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4014_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2024.06.016","volume":"31","author":"T Umemura","year":"2025","unstructured":"Umemura T, Kakizaki H, Mutoh Y, et al. Effectiveness and safety of the simulation-based first-dose design of voriconazole. J Infect Chemother. 2025;31(1):102453. https:\/\/doi.org\/10.1016\/j.jiac.2024.06.016.","journal-title":"J Infect Chemother"},{"issue":"1","key":"4014_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s11096-024-01822-x","volume":"47","author":"M Swartling","year":"2025","unstructured":"Swartling M, Hamberg A, Furebring M, et al. Model-informed precision dosing of vancomycin in clinical practice: an intervention development study. Int J Clin Pharm. 2025;47(1):178\u201386. https:\/\/doi.org\/10.1007\/s11096-024-01822-x.","journal-title":"Int J Clin Pharm"},{"issue":"8","key":"4014_CR21","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-1341","volume":"10","author":"G Zhao","year":"2022","unstructured":"Zhao G, Chen M, Sun L, et al. Analysis of influencing factors on the plasma concentration of first-line anti-tuberculosis drugs-a single-center retrospective cohort study. Ann Transl Med. 2022;10(8):461. https:\/\/doi.org\/10.21037\/atm-22-1341.","journal-title":"Ann Transl Med"},{"issue":"4","key":"4014_CR22","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/pubmed\/fdaa146","volume":"43","author":"SA Kassim","year":"2021","unstructured":"Kassim SA, Cote A, Kassim SM, et al. Factors influencing treatment outcomes of tuberculosis patients attending health facilities in Galkayo puntland, Somalia. J Public Health. 2021;43(4):887\u201395. https:\/\/doi.org\/10.1093\/pubmed\/fdaa146.","journal-title":"J Public Health"},{"key":"4014_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1454207","volume":"11","author":"J Tan","year":"2024","unstructured":"Tan J, Shi X, Pi Y, et al. Nutritional scores predict the prognosis of patients with pulmonary tuberculosis. Front Nutr. 2024;11:1454207. https:\/\/doi.org\/10.3389\/fnut.2024.1454207.","journal-title":"Front Nutr"},{"key":"4014_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2023.102367","volume":"141","author":"RM Xavier","year":"2023","unstructured":"Xavier RM, Sharumathi SM, Kanniyappan Parthasarathy A, et al. Limited sampling strategies for therapeutic drug monitoring of anti-tuberculosis medications: a systematic review of their feasibility and clinical utility. Tuberculosis. 2023;141:102367. https:\/\/doi.org\/10.1016\/j.tube.2023.102367.","journal-title":"Tuberculosis"},{"issue":"9","key":"4014_CR25","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1093\/jac\/dky152","volume":"73","author":"KE Stott","year":"2018","unstructured":"Stott KE, Pertinez H, Sturkenboom MGG, et al. Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. J Antimicrob Chemother. 2018;73(9):2305\u201313. https:\/\/doi.org\/10.1093\/jac\/dky152.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"4014_CR26","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1007\/s00228-024-03749-8","volume":"80","author":"M Sarkar","year":"2024","unstructured":"Sarkar M, Sarkar J. Therapeutic drug monitoring in tuberculosis. Eur J Clin Pharmacol. 2024;80(11):1659\u201384. https:\/\/doi.org\/10.1007\/s00228-024-03749-8.","journal-title":"Eur J Clin Pharmacol"},{"key":"4014_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.932686","volume":"13","author":"B Chen","year":"2022","unstructured":"Chen B, Shi H, Feng MR, et al. Population pharmacokinetics and pharmacodynamics of Isoniazid and its metabolite acetylisoniazid in Chinese population. Front Pharmacol. 2022;13:932686. https:\/\/doi.org\/10.3389\/fphar.2022.932686.","journal-title":"Front Pharmacol"},{"key":"4014_CR28","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ijid.2022.11.033","volume":"126","author":"R Perumal","year":"2023","unstructured":"Perumal R, Naidoo K, Naidoo A, et al. The impact of enteral feeding and therapeutic monitoring of rifampicin with dose escalation in critically ill patients with tuberculosis. Int J Infect Dis. 2023;126:174\u201380. https:\/\/doi.org\/10.1016\/j.ijid.2022.11.033.","journal-title":"Int J Infect Dis"},{"issue":"4","key":"4014_CR29","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ijtb.2019.11.005","volume":"66","author":"R Prasad","year":"2019","unstructured":"Prasad R, Singh A, Gupta N. Adverse drug reactions in tuberculosis and management. Indian J Tuberc. 2019;66(4):520. https:\/\/doi.org\/10.1016\/j.ijtb.2019.11.005.","journal-title":"Indian J Tuberc"},{"issue":"5","key":"4014_CR30","doi-asserted-by":"publisher","first-page":"499","DOI":"10.5588\/ijtld.19.0063","volume":"24","author":"AKJ Maug","year":"2020","unstructured":"Maug AKJ, Hossain MA, Gumusboga M, et al. First-line tuberculosis treatment with double-dose rifampicin is well tolerated. Int J Tuberc Lung Dis. 2020;24(5):499\u2013505. https:\/\/doi.org\/10.5588\/ijtld.19.0063.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"4014_CR31","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S2213-2600(24)00107-3","volume":"12","author":"TS Ryckman","year":"2024","unstructured":"Ryckman TS, Salazar-Austin N. High-dose rifampicin to treat tuberculosis infection: potential and pitfalls. Lancet Respir Med. 2024;12(6):420\u20131. https:\/\/doi.org\/10.1016\/S2213-2600(24)00107-3.","journal-title":"Lancet Respir Med"},{"key":"4014_CR32","volume-title":"Tuberculosis: module 4: treatment-drug-resistant tuberculosis treatment, 2022 update","author":"WHO consolidated guidelines on","year":"2022","unstructured":"WHO consolidated guidelines on. Tuberculosis: module 4: treatment-drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022."},{"issue":"1","key":"4014_CR33","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2386030","volume":"56","author":"S Leo","year":"2024","unstructured":"Leo S, Narasimhan M, Rathinam S, et al. Biomarkers in diagnosing and therapeutic monitoring of tuberculosis: a review. Ann Med. 2024;56(1):2386030. https:\/\/doi.org\/10.1080\/07853890.2024.2386030.","journal-title":"Ann Med"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-04014-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-025-04014-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-04014-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T10:16:50Z","timestamp":1763461010000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-025-04014-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4014"],"URL":"https:\/\/doi.org\/10.1186\/s12890-025-04014-z","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"23 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"I confirm that I have read the Editorial Policy pages. The study protocol was approved by the Ethics Committee for Medical Scientific Research of Xi\u2019an Chest hospital (Approval number: S2023-0002). This study was conducted in accordance with the declaration of Helsinki. Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"529"}}